These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 26398717)

  • 1. Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis.
    Al-Khafaji K; Mutyala M; Al-Khafaji N; Harper Y; Ismail I; Hakim H; Arora RR
    Am J Ther; 2017; 24(6):e730-e736. PubMed ID: 26398717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet protease-activated receptor antagonism in cardiovascular medicine.
    Wiisanen ME; Moliterno DJ
    Coron Artery Dis; 2012 Sep; 23(6):375-9. PubMed ID: 22781741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives.
    Moschonas IC; Goudevenos JA; Tselepis AD
    Int J Cardiol; 2015 Apr; 185():9-18. PubMed ID: 25777282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis.
    Leonardi S; Becker RC
    Handb Exp Pharmacol; 2012; (210):239-60. PubMed ID: 22918734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.
    Moon JY; Franchi F; Rollini F; Angiolillo DJ
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):23-37. PubMed ID: 28565918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent.
    French SL; Arthur JF; Tran HA; Hamilton JR
    Blood Rev; 2015 May; 29(3):179-89. PubMed ID: 25467961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vorapaxar (Zontivity) for the Prevention of Thrombotic Cardiovascular Events.
    Barry KA; Somerville NJ
    Am Fam Physician; 2015 Aug; 92(4):304-5. PubMed ID: 26280236
    [No Abstract]   [Full Text] [Related]  

  • 8. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
    Arif SA; D'Souza J; Gil M; Gim S
    Am J Health Syst Pharm; 2015 Oct; 72(19):1615-22. PubMed ID: 26386102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials.
    Capodanno D; Bhatt DL; Goto S; O'Donoghue ML; Moliterno DJ; Tamburino C; Angiolillo DJ
    J Thromb Haemost; 2012 Oct; 10(10):2006-15. PubMed ID: 22845871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.
    Morrow DA; Scirica BM; Fox KA; Berman G; Strony J; Veltri E; Bonaca MP; Fish P; McCabe CH; Braunwald E;
    Am Heart J; 2009 Sep; 158(3):335-341.e3. PubMed ID: 19699854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555.
    Leonardi S; Tricoci P; Becker RC
    Drugs; 2010 Oct; 70(14):1771-83. PubMed ID: 20836572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorapaxar in the secondary prevention of atherothrombosis.
    Tantry US; Liu F; Chen G; Gurbel PA
    Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1293-305. PubMed ID: 26559689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of vorapaxar for the prevention of atherothrombotic events.
    Wang A
    Expert Opin Pharmacother; 2015; 16(16):2509-22. PubMed ID: 26480240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel anti-platelet agents: focus on thrombin receptor antagonists.
    de Souza Brito F; Tricoci P
    J Cardiovasc Transl Res; 2013 Jun; 6(3):415-24. PubMed ID: 23435863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.
    Franchi F; Rollini F; Park Y; Angiolillo DJ
    Future Cardiol; 2015 Sep; 11(5):547-64. PubMed ID: 26406386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events.
    Tomasello SD; Angiolillo DJ; Goto S
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1557-67. PubMed ID: 20979570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorapaxar for the reduction of atherothrombotic events.
    Diaz-Ricart M; Escolar G
    Drugs Today (Barc); 2014 Nov; 50(11):747-56. PubMed ID: 25525635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition.
    Ungar L; Rodriguez F; Mahaffey KW
    Coron Artery Dis; 2016 Nov; 27(7):604-15. PubMed ID: 27398626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorapaxar: A Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events.
    Lam S; Tran T
    Cardiol Rev; 2015; 23(5):261-7. PubMed ID: 25923910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet thrombin receptor antagonism and atherothrombosis.
    Angiolillo DJ; Capodanno D; Goto S
    Eur Heart J; 2010 Jan; 31(1):17-28. PubMed ID: 19948715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.